CC Chemokine Receptor 7–dependent and –independent Pathways for Lymphocyte Homing: Modulation by FTY720 by Henning, Golo et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/12/1875/07 $5.00
Volume 194, Number 12, December 17, 2001 1875–1881
http://www.jem.org/cgi/content/full/194/12/1875
 
Brief Deﬁnitive Report
 
1875
 
CC Chemokine Receptor 7–dependent and –independent 
Pathways for Lymphocyte Homing: Modulation by FTY720
 
Golo Henning,
 
1 
 
Lars Ohl,
 
1 
 
Tobias Junt,
 
2 
 
Phillip Reiterer,
 
3
 
Volker Brinkmann,
 
4 
 
Hideki Nakano,
 
5 
 
Werner Hohenberger,
 
1
 
Martin Lipp,
 
3 
 
and Reinhold Förster
 
1
 
1
 
Section of Experimental Surgery and Immunology, University Clinic for Surgery and
Nikolaus-Fiebiger-Zentrum, 91054 Erlangen, Germany
 
2
 
Institute for Experimental Immunology, Department of Pathology, University Hospital, CH-8091 
Zürich, Switzerland
 
3
 
Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany
 
4
 
Novartis Pharma AG, CH-4002 Basel, Switzerland
 
5
 
Department of Immunology, Toho University School of Medicine, Ota-Ku, Tokyo 143-8540, Japan
 
Abstract
 
Cognate interaction of chemokine receptor CCR7 on lymphocytes with its ligands CCL19
and CCL21 expressed on high endothelial venules (HEVs) is essential for effective migration of
T and B cells across HEVs into secondary lymphoid organs. 
 
Plt
 
 mice, which lack expression of
CCL19 and CCL21-ser, both ligands for CCR7 on HEVs, as well as CCR7-deficient mice,
have a defective cell migration and reduced homing of lymphocytes. FTY720, a novel immu-
nosuppressant, causes a reduction of lymphocytes in peripheral blood and tissues and their se-
questration into lymphoid tissues. In this study we demonstrate that FTY720 rescues the hom-
ing defect in both CCR7
 
 
 
/
 
 
 
 mice and 
 
plt
 
 mice. After FTY720 treatment, the number of
CD4
 
 
 
 and CD8
 
 
 
 T cells as well as B cells in peripheral blood is reduced while pertussis toxin–
sensitive homing into peripheral lymph nodes, mesenteric lymph node, and Peyer’s patches is
increased. Immunohistology demonstrates that FTY720 enables these cells to enter lymphoid
tissue through HEVs. Thus, our data suggest an alternative G-
 
 
 
i-dependent, CCR7-CCL19/
CCL21-independent mechanism for lymphocyte homing through HEVs which is strongly
augmented in the presence of FTY720.
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Introduction
 
Migration of T and B lymphocytes into secondary lym-
phoid organs, encounter with antigen-presenting cells, and
subsequent release into the bloodstream and peripheral tis-
sues is required for the induction of an antigen-specific im-
mune response. The homing of lymphocytes into LNs is
tightly regulated and follows defined pathways. While
memory T cells enter LNs by afferent lymphatic vessels,
naive T cells as well as B cells migrate directly from the
blood stream into secondary lymphoid tissue by extravasa-
tion through specialized high endothelial venules (HEVs;
reference 1). This process is controlled at a molecular level
by cellular interactions of adhesion molecules such as selec-
tins and integrins and involves regulation of cellular traf-
ficking by chemokines and their receptors (2). Chemokines
are a family of small chemoattractant proteins that bind to
G protein–coupled receptors expressed on target cells, thus
allowing these cells to follow chemokine concentration
gradients into selected tissues. Chemokines guide lympho-
cytes to secondary lymphoid organs and to specific mi-
croenvironments within these organs, such as T cell zone,
follicles, etc., thereby coordinating the appropriate interac-
tions of T cells, dendritic cells (DCs), and B cells required
for the initiation of an immune response (3, 4).
Specifically, it has been shown that the chemokine re-
ceptor CCR7 and its ligands, the chemokines EBV-
induced molecule 1 ligand chemokine (ELC/CCL19) and
secondary lymphoid tissue chemokine (SLC/CCL21) play
a decisive role in the migration of T and B cells through
HEVs into LNs and to specialized microenvironments
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within these tissues. (3, 5). CCL19 and CCL21 are ex-
pressed on HEVs in Peyer’s patches (PPs) and peripheral
LNs (PLNs) as well as on stroma cells and DCs within the
T cell zones of LNs, PPs, and spleen (6, 7). Analysis of
transgenic CCR7-deficient mice (CCR7
 
 
 
/
 
 
 
 mice) re-
vealed significantly increased numbers of T cells in periph-
eral blood, while the number of T cells in LNs is reduced.
It could be demonstrated that the migration of DCs, T, and
B cells into PLNs and PPs is impaired (3). Similarly, a mu-
tant mouse, the 
 
plt
 
 (paucity of LN T cells) mouse, shows
increased numbers of T cells in peripheral blood and re-
duced numbers of T cells in LNs. These mice fail to express
detectable levels of CCL19 and CCL21-ser in lymphatic
organs and suffer from a homing defect resembling the de-
fect of CCR7
 
 
 
/
 
 
 
 mice (5).
FTY720 (2-amino-2-[2-(4-octylphenyl) ethyl] propane-
1,3-diol) is a novel immunosuppressant that is thought to
act by accelerating lymphocyte homing into LNs and PPs
and sequestering circulating lymphocytes within these tis-
sues (8, 9). FTY720 is a synthetic immunosuppressant ob-
tained by chemical modification of a product isolated
from filamentous fungus 
 
Isaria sinclairii
 
 and shows potent
immunosuppressive effects in skin and cardiac allograft
models (10). Treatment with FTY720 induces a marked
reduction of peripheral blood lymphocytes, especially T
cells (9).
Regulation of lymphocyte trafficking by chemokines is
to a certain degree redundant: some chemokines bind sev-
eral chemokine receptors, while some receptors have sev-
eral, apparently functionally equivalent ligands. Further-
more, lymphocyte trafficking is also regulated by and
dependent upon interactions of various adhesion mole-
cules. How these mechanisms depend on one another and
to what degree they are redundant is not entirely clear. In
this study we show that FTY720 treatment of CCR7
 
 
 
/
 
 
 
mice and 
 
plt
 
 mice restores the lymphocyte homing defect
in a pertussis toxin–sensitive manner, thus pointing to an
alternative, CCR7-CCL19/CCL21-independent mecha-
nism for lymphocyte migration via HEVs into secondary
lymphoid tissue.
 
Materials and Methods
 
CCR7
 
 
 
/
 
 
 
 mice on a mixed Balb/c-129SV background and
corresponding wild-type mice as well as 
 
plt
 
 mice on a C57BL6
background and C57BL6 mice were maintained under specific
pathogen-free conditions. FTY720 (Novartis) was dissolved in
distilled water and administered orally by gavage or in drink-
ing water. Control animals received the vehicle only. CFDA-
SE (carboxyfluorecein diacetate succinimidyl ester [CFSE])
was obtained from Molecular Probes. The antibodies used for
flow cytometry and immunohistology have been described
(3, 4).
 
Cell Counts and Flow Cytometry.
 
Peripheral blood was col-
lected by retro-orbital venous plexus sampling into tubes contain-
ing sodium citrate. Erythrocytes were removed by NH
 
4
 
Cl lysis.
Single cell suspensions of lymphoid organs were prepared by
mincing and passing through nylon mesh. Cell counts were de-
termined using a Neubauer chamber. Differential cell counts of
CD4
 
 
 
, CD8
 
 
 
, B220
 
 
 
, CD11b
 
 
 
, and CD43
 
 
 
 cells were analyzed
by flow cytometry.
To analyze migration patterns of lymphocytes in vivo, CFDA-
SE–labeled lymphocytes were injected into recipient animals and
their tissue distribution was then evaluated by immunohistology
or differential flow cytometry of single cell suspension of isolated
organs. Lymphocytes were isolated by preparing single cell sus-
pensions from spleen and MLNs of either CCR7
 
 
 
/
 
 
 
 or wild-
type mice. Cells were labeled for 6 min at 37
 
 
 
C with 50 
 
 
 
M
CFDA-SE. Washed cells were suspended in RPMI medium and
treated in vitro with FTY720 and/or pertussis toxin for the indi-
cated time periods at 37
 
 
 
C, washed, counted, and injected into
retro-orbital venous plexus of recipient mice. Recipient mice
were killed after the indicated time periods and lymphoid organs
were removed and single cell suspensions were prepared. Differ-
ential cell counts were analyzed by flow cytometry using anti-
bodies specific for CD4, CD8, or B220. Based on the green fluo-
rescence of CFDA-SE labeling and the far red labeling of
antibodies, the percentage of transferred CD4
 
 
 
 T cells, CD8
 
 
 
 T
cells, or B cells was determined.
To determine the localization of transferred cells within lym-
phoid tissues, lymphoid organs were removed from recipient
mice, embedded in Tissue-Tek
 
® 
 
(Vogel Giessen) and snap frozen
on liquid nitrogen. Cryostat sections (8-
 
 
 
m thick) on slides were
stained for immunohistology as described earlier (3, 4).
 
Results and Discussion
 
Hallmark of the action of FTY720 is a reduction of lym-
phocytes in peripheral blood and tissues and their seques-
tration into lymphoid tissues (9). As CCR7
 
 
 
/
 
 
 
 mice have a
defective cell migration and reduced homing of lympho-
cytes (3), we were interested whether FTY720 has an effect
on the homing of CCR7-deficient lymphocytes.
To test whether the FTY720-induced reduction of pe-
ripheral lymphocytes is dependent on CCR7-mediated
homing into lymphoid organs, CCR7
 
 
 
/
 
 
 
 mice and wild-
type controls were given FTY720 orally over a period of
72 h and the numbers of CD4
 
 
 
 T cells, CD8
 
 
 
 T cells, and
B220
 
 
 
 cells in peripheral blood were determined by cell
counting and flow cytometry. Surprisingly, the lymphocyte
homing defect of CCR7
 
 
 
/
 
 
 
 mice was alleviated by
FTY720 treatment. Compared with wild-type mice, the
reduction of lymphocytes in peripheral blood of CCR7
 
 
 
/
 
 
 
mice follows delayed kinetics and is not as complete:
whereas in wild-type mice a nearly complete disappearance
of CD4
 
 
 
 T cells could be observed after 24 h of FTY720
treatment, CD4
 
 
 
 cell counts in CCR7
 
 
 
/
 
 
 
 mice were con-
tinually reduced to 
 
 
 
10% over a period of 72 h (Fig. 1 A).
At the same time flow cytometry with staining of CD43
and CD11b revealed neutrophil and macrophage popula-
tions were not affected by FTY720 (data not shown). Anal-
ysis of the short term effects of FTY720 treatment con-
firmed that both CD4
 
 
 
 T cells and B cells of wild-type
mice left the bloodstream noticeably faster than those of
CCR7
 
 
 
/
 
 
 
 mice (Fig. 1 B), thus suggesting both a CCR7-
dependent as well as an independent component of FTY-
mediated homing of lymphocytes.
To analyze homing of lymphocytes to lymphatic tissue in
CCR7
 
 
 
/
 
 
 
 compared with wild-type mice, animals were 
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treated with FTY720 and differential cell counts in second-
ary lymphoid organs were analyzed. The homing of CD4
 
 
 
T cells was affected the most by FTY720. A dramatic, two-
to threefold increase in the number of CD4
 
 
 
 T cells in
PLNs and PPs could be observed after FTY720 treatment of
CCR7
 
 
 
/
 
 
 
 mice (Fig. 2). In wild-type mice the numbers of
CD4
 
 
 
 T cells in PLN increased by 
 
 
 
50%. This lesser in-
crease compared with CCR7
 
 
 
/
 
 
 
 mice is probably due to
the fact that the PLNs of wild-type mice harbor much larger
numbers of lymphocytes than CCR7
 
 
 
/
 
 
 
 mice (Fig. 2). In
terms of absolute numbers of increased CD4
 
 
 
 T cells in LNs
the effects of FTY720 in CCR7
 
 
 
/
 
 
 
 mice and wild-type
mice were on a similar scale: on average 5.8 
 
  
 
1.7 
 
  
 
10
 
5
 
CD4
 
 
 
 T cells/LN migrated into PLNs of CCR7
 
 
 
/
 
 
 
 mice,
6.4 
 
  
 
3.4 
 
  
 
10
 
5
 
 CD4
 
 
 
 T cells/LN migrated into PLNs of
wild-type mice (average of six PLN each from three ani-
mals 
 
 
 
 SD). On CD8
 
 
 
 T cells the effects of FTY720 were
similar, though not quite as strong as on CD4
 
 
 
 T cells.
To determine whether CCR7-deficient lymphocytes
migrate into LNs through HEVs or afferent lymphatics,
splenocytes from CCR7
 
 
 
/
 
 
 
 mice were labeled with
CFSE, treated with FTY720 or medium only ex vivo, and
injected intravenously into wild-type recipient mice.
Counterstaining of HEVs on histological sections revealed
that labeled, FTY720-treated CCR7-deficient donor cells
appeared in lymphoid tissue surrounding HEVs (Fig. 3 A)
while untreated cells were largely prevented from entering
lymphoid organs (Fig. 3 B). Furthermore, the migration
of labeled, CCR7-deficient donor cells through the endo-
thelial walls could be visualized, thus demonstrating that
FTY720 enables lymphocytes to enter lymphoid tissue
through HEVs independently of CCR7 (Fig. 3 A, insert).
As the number of lymphocytes in PLNs and PPs was in-
creased by FTY720 treatment, it was of interest to see if
the structure and distribution of lymphocytes within these
organs was altered. Within the scope of our experiments
the microarchitecture of LNs and spleen apparently re-
mained unaltered after FTY720 treatment (compare Fig.
3, C and D). Likewise, no changes in lymphoid organ
Figure 1. FTY720 treatment reduces lymphocyte counts in CCR7 / 
mice. Peripheral blood was taken before FTY720 administration and at
indicated time points afterwards and analyzed by cell counting and flow
cytometry. (A) CCR7 /  and wild-type mice were given FTY720 in
drinking water (2  g/ml; closed symbols) or water only (open symbols).
Mean values of five animals each are represented and error bars indicate
standard deviation. (B) CCR7 /  and wild type mice were given
FTY720 orally once by gavage (6  g/animal) and then in drinking water
(2  g/ml) or vehicle only for control animals. Mean values of four ani-
mals each are represented, and cell number is expressed as percentage of
matching untreated control animals.
Figure 2. FTY720 treatment increases homing of lymphocytes into
PLNs and Peyer’s patches in CCR7 /  mice. CCR7 /  and wild-type
mice were given FTY720 (black bars) orally once by gavage (6  g/ani-
mal) and then in drinking water (2  g/ml) or vehicle only (white bars).
After 18 h axilary LN (Ax.), brachial LN (Br.), and Peyer’s patches (PP)
were removed by dissection, and differential cell counts from single cell
suspensions were determined by cell counting and flow cytometry. Mean
values of six organs from three animals   SD are shown. 
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structure after FTY720 treatment could be detected in
wild-type mice (not shown). This suggests that although
FTY720 can restore lymphocyte trafficking via CCR7-
independent mechanisms it is not sufficient to substitute
the requirement for CCR7 for the maintenance of normal
LN architecture.
To test whether CCR7-independent homing of lym-
phocytes is mediated by G protein–coupled receptors, sple-
nocytes from CCR7
 
 
 
/
 
 
 
 mice were labeled with CFSE,
treated ex vivo with FTY720 and/or pertussis toxin, and
injected intravenously into CCR7
 
 
 
/
 
 
 
 recipient mice that
had been given a single oral dose of FTY720 or vehicle
control. After 4 h the lymphoid organs of recipient mice
were removed and percentage of labeled infiltrated CD4
 
 
 
cells in peripheral LNs was determined by flow cytometry.
After pertussis toxin treatment the number of infiltrated
cells in FTY720-treated recipient animals was reduced
from 
 
 
 
1.2 
 
 
 
 10
 
4
 
 cells/LN to 0.4   104 cells and in vehicle
treated animals from 0.8   104 cells to 0.4   104 cells (Fig.
4). These data suggest that FTY720 induces lymphocyte
homing mediated by G- i–coupled receptors.
Plt mice are characterized by a lack of expression in sec-
ondary lymphoid organs and on HEVs of the chemokines
CCL19 and CCL21-ser both of which are ligands for
CCR7 and on HEV. As we observed that FTY720 induces
lymphocyte homing independently of CCR7, it was of in-
terest to determine whether this effect was also indepen-
dent of the known ligands of CCR7. Plt mice and wild-
type controls were given FTY720 orally over a period of
72 h and the numbers of CD4  T cells, CD8  T cells,
and B220  cells in peripheral blood were determined by
differential cell counts. The number of CD4 , CD8 ,
and B220  lymphocytes were markedly decreased after
Figure 3. (A and B) CCR7 / 
lymphocytes are able to migrate
through HEVs into secondary
lymphoid tissue after FTY720
treatment. Splenocytes from a
CCR7 /  donor animal were
labeled with CFDA-SE. Cells
were treated ex vivo with
FTY720 (0.5  M, 37 C, 2 h)
or incubated in medium only
(37 C, 2 h) and injected into
wild-type recipient mice. After
2.5 h, LNs were obtained by dis-
section and cryostat sections
were prepared. HEVs were
stained with MECA-79 mAb
and counterstaining was against
CD90 (Thy1). (A) FTY720-
treated CCR7 /  cells migrate
through HEVs (insert, 40  orig-
inal magnification) and into sur-
rounding tissue (large panel,
10  original magnification). (B)
Untreated CCR7 /  cells do
not migrate into tissue surround-
ing HEVs (10  magnification).
Representative results of inde-
pendent experiments with four
recipient animals each (treated
and untreated) are shown. (C
and D) Increased numbers of T
cells migrate into PLNs of
CCR7 /  mice but their tissue distribution is not altered after FTY720 treatment. CCR7 /  mice were treated with FTY720 (2  g/ml) (C) or vehicle
only (D) for 10 d. LNs were obtained by dissection and cryostat sections were prepared. T cells were stained with anti-Thy 1-Cy5, B cells were stained
with anti-IgD-FITC, and DCs were stained with CD11c-biotin/streptavidin-Cy3.
Figure 4. FTY720-induced homing of CCR7 /  T cells is pertussis
toxin sensitive. Splenocytes from CCR7 /  donor animals were labeled
with CFDA-SE. Cells were treated ex vivo with FTY720 (0.5  M,
37 C, 3 h), and/or pertussis toxin (PTX; 20 ng/ml, 37 C, 3 h) or incu-
bated in medium only (37 C, 3 h) and injected into wild-type recipient
mice. Recipient mice receiving FTY720 treated cells were given
FTY720 once orally by gavage (6  g/animal) 2 h before transfer of la-
beled cells. Recipient mice receiving cells not treated with FTY720 were
given vehicle only by gavage. 4 h after the transfer, LNs were obtained by
dissection and the number of CD4  CFSE stained T cells was determined
by cell counting and flow cytometry. Mean values of six LNs from three
animals are shown, error bars indicate SD.1879 Henning et al.
FTY720 treatment in peripheral blood of plt mice with a
similar kinetic as that of CCR7-deficient mice while cell
counts in untreated controls remained constant (Fig. 5).
The similar kinetics and level of reduction of peripheral
lymphocyte counts in plt and CCR7 /  mice lead us to the
assumption that FTY720 acts in both these animal models
in a similar fashion, although it has not yet been proven
formally that FTY720 accelerates lymphocyte homing in
plt mice as well. Taken together, these results demonstrate
that FTY720 promotes lymphocyte homing in a CCR7-
CCL19/CCL21-independent manner.
Treatment of CCR7 /  and plt mice with FTY720, a
novel immunosuppressant, resulted in a marked decrease of
all lymphocytes in peripheral blood. Compared with wild-
type mice subjected to the same treatment protocol, the re-
duction of lymphocytes in CCR7-deficient and plt mice
followed slower kinetics. Also, the overall level of reduc-
tion in wild-type mice was higher than in CCR7 /  mice.
Thus, FTY720-induced lymphocyte migration seems to
have a CCR7-dependent as well as a CCR7-independent
component. Similarly, it could be demonstrated that after
FTY720 treatment homing into secondary lymphoid tis-
sues was increased in CCR7 /  mice. These observations
are in accordance with previous studies, showing that
FTY720 induces homing of lymphocytes into PLNs and
PPs, but does not impede the generation of an immune re-
sponse within secondary lymphoid organs (11, 12). Our
observations suggest that aside from accelerating lympho-
cyte homing FTY720 does not induce gross alterations of
the architecture of secondary lymphoid organs. Taken to-
gether, these findings imply that FTY720 acts indeed by se-
questering lymphocytes in secondary lymphoid organs,
thereby preventing their migration toward sites of infection
and allograft rejection.
Furthermore, the data show that the FTY720-induced,
CCR7-independent homing into PLNs occurs at the
HEVs. Homing of naive T cells and B cells into these tis-
sues is thought to proceed in a multistep fashion requiring
the interactions of selectins, integrins, and chemokine re-
ceptors with their corresponding ligands. As yet, the mo-
lecular target of FTY720 is unknown. Homing of CD62L 
(L-selectin) T cells into PPs is increased by FTY720 but
expression levels of CD62L, CD49d (VLA4), and CD11a
(LFA1) were not altered by FTY720 (9). The fact that
FTY720-induced, CCR7-independent homing into PLNs
is sensitive to pertussis toxin demonstrates that FTY720 acts
in a specific, receptor-dependent manner. As FTY720 is an
amphiphilic molecule, it cannot be excluded that unspe-
cific lipophilic interactions of the hydrocarbon moiety of
FTY720 with components of the cell membrane also con-
tribute to the mechanisms of this drug (10). Using pertussis
toxin as an inhibitor, it was also revealed that there
is a basal, CCR7-independent trafficking of lymphocytes
through HEVs, which is mediated by G- i-coupled recep-
tors. Along with the different kinetics of lymphocyte hom-
ing of CCR7 /  and wild-type mice, this shows there are
additional mechanisms responsible for lymphocyte homing,
in addition to CCR7-mediated homing into secondary
lymphoid organs. This is also underlined by the fact that
the effects of FTY720 treatment vary for different cell pop-
ulations: CD4  T cells are affected the most, B cells to a
lesser degree. Interestingly, both in CCR7 /  and plt mice
the overall number of B cells in secondary lymphoid organs
is not reduced, as opposed to T cells (3, 5). B cells are
known to enter LNs through HEVs, but apparently are
able to do so independently of CCR7 and CCL19/
CCL21. Perhaps this CCR7-independent mechanism is
amplified by FTY720 treatment, which would also explain
the observed increase in B cell homing.
Other chemokine receptors possibly involved in CCR7
independent homing of T and B lymphocytes include
CXCR3, CXCR4 (which is of specific interest since it is
also expressed by naive T cells), as well as CCR5 and
CCR6. While these chemokine receptors are expressed
by T and B cells, none of their known ligands are ex-
pressed on HEVs. CXCL9 (Mig), CXCL10 (IP-10), and
CXCL11 (I-TAC), all ligands for CXCR3, are IFN-
inducible chemokines attracting T cells to inflammatory
sites (13). SDF-1, the chemokine recognized by CXCR4
seems not to be expressed on HEVs (our unpublished ob-
servation), and the main ligands for CCR5, CCL3 (mac-
rophage inflammatory protein [MIP]-1 ), CCL4 (MIP-
1 ), CCL5 (RANTES [regulated upon activation, normal
T cell expressed and secreted]), are involved in inflamma-
tory processes and are also not found on HEVs. Similarly,
CCL20 (Mip-3 , LARC), which is bound by CCR6 also
directs inflammatory cell migration but is not known to
be involved in lymphocyte homing to LNs (14). This sug-
gests, that FTY720 might act on the chemokine system as
a whole rather than on a specific chemokine receptor.
This conclusion is also supported by the following obser-
vations: (a) while the effect of FTY720 on lymphocyte
chemotaxis in vitro is most pronounced toward CCL19
and CCL21, it has also been shown that the chemotaxis to
other chemokines is also increased by FTY720 (unpub-
lished data), and (b) although FTY720 treatment aug-
ments lymphocyte chemotaxis toward CCL19/CCL21 in
vitro (unpublished data), it shows an even more dramatic
effect in vivo in mice lacking CCR7 or CCL19 and
CCL21.
Figure 5. FTY720 treatment reduces lymphocyte counts in plt mice.
Plt mice were given FTY720 in drinking water (2  g/ml; closed symbols)
or water only (open symbols). Peripheral blood was taken before FTY720
administration and at indicated time points afterwards and analyzed by cell
counting and flow cytometry. Mean values of three animals each are rep-
resented and error bars indicate SD.1880 CCR7-dependent and -independent Lymphocyte Homing: Modulation by FTY720
Alternatively, mechanisms independent of the chemo-
kine system might be involved. A host of other receptors
mediate cell motility, such as Sphingosine-1 phosphate re-
ceptors, opioid receptors, and others which share G- i–
coupled signaling as a common denominator (15, 16).
Among these, Sphingosine-1 phosphate receptors are of
special interest, as some of them, such as EDG-6, are ex-
pressed specifically by various lymphocyte subsets and are
known to mediate activation of lymphocytes (17).
These findings might have potentially interesting conse-
quences for further therapeutic uses of FTY720: it is
known that some cytotoxic CCR7-negative effector T
cells are unable to enter secondary lymphoid organs, and
that these organs are sites of persistence and active replica-
tion of lymphotropic viruses, such as HIV,CMV, EBV, or
measles virus (18, 19, 20). Apparently, these viruses are able
to utilize these sites as part of their immune evasion strategy
(18, 21). It would be of interest to see if FTY720 treatment
enables effector T cells to reenter into secondary lymphoid
organs and if these cells mount an antiviral immune re-
sponse at the site of viral replication. Further studies are re-
quired to find out whether the immunosuppressive effect
of FTY720 is solely due to the sequestration of lympho-
cytes, or whether it interferes with additional lymphocyte
activation pathways.
In summary, our data revealed a novel G- i–coupled,
CCR7-CCL19/CCL21–independent mechanism of lym-
phocyte homing through HEVs which is strongly
enhanced in the presence of the immunosuppressant
FTY720. This sheds new light on the mechanism through
which FYT720 acts. At the same time, it poses new ques-
tions which need to be addressed to understand how differ-
ent mechanisms cooperate to regulate the homing of vari-
ous lymphocyte subsets.
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